EndoStim II Secures CE Mark Approval
EndoStim has CE Mark approval for its EndoStim II, a second-generation lower esophageal sphincter stimulation system for the treatment of gastroesophageal reflux disease, the devicemaker based in St. Louis, Mo., and Nijmegen, Netherlands, announced Monday. The company already launched the device in certain European markets.
The device is thinner and smaller than its previous incarnation, allowing for increased patient comfort, and featuring improved MRI compatibility, the company says.
The EndoStim system targets a patient’s nonworking LES muscle between the stomach and esophagus which can cause stomach substances to flow backward into the esophagus leading to inflammation and damage.
In the U.S., the system has been designated for investigational use only. — Jason Scott